Could a common transplant drug tame dangerous brain aneurysms?
NCT ID NCT04141020
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether sirolimus, a drug used to prevent organ rejection, can reduce harmful inflammation inside brain aneurysms. Researchers will give the drug to some patients before standard surgery or coiling and compare tissue and blood samples to those not receiving the drug. The goal is to see if sirolimus changes gene activity linked to aneurysm growth and rupture risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus (also known as Rapamune), an oral medication that may reduce inflammation and abnormal cell growth in blood vessels.
- What this could lead to
- If successful, this could point toward a drug treatment to stabilize brain aneurysms and reduce the risk of rupture, potentially lowering the need for surgery.
- What could go wrong
- This is a small, early-phase study focused on molecular changes, not on preventing rupture. Sirolimus has side effects like mouth sores and increased infection risk, and it may not show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL ANEURYSM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.